Adaptimmune Therapeutics plc (473A) - Total Assets
Based on the latest financial reports, Adaptimmune Therapeutics plc (473A) holds total assets worth €130.63 Million EUR (≈ $152.72 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Adaptimmune Therapeutics plc (473A) net assets for net asset value and shareholders' equity analysis.
Adaptimmune Therapeutics plc - Total Assets Trend (2016–2024)
This chart illustrates how Adaptimmune Therapeutics plc's total assets have evolved over time, based on quarterly financial data.
Adaptimmune Therapeutics plc - Asset Composition Analysis
Current Asset Composition (December 2024)
Adaptimmune Therapeutics plc's total assets of €130.63 Million consist of 76.5% current assets and 23.5% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 37.1% |
| Accounts Receivable | €1.45 Million | 0.6% |
| Inventory | €7.32 Million | 3.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €3.88 Million | 1.6% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Adaptimmune Therapeutics plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Adaptimmune Therapeutics plc worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Adaptimmune Therapeutics plc's current assets represent 76.5% of total assets in 2024, a decrease from 84.8% in 2016.
- Cash Position: Cash and equivalents constituted 37.1% of total assets in 2024, down from 67.7% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 3.0% of total assets.
Adaptimmune Therapeutics plc Competitors by Total Assets
Key competitors of Adaptimmune Therapeutics plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
| No similar companies found. | ||
Adaptimmune Therapeutics plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.52 | 3.09 | 12.23 |
| Quick Ratio | 1.29 | 3.09 | 12.16 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €26.60 Million | €171.70 Million | €391.83 Million |
Adaptimmune Therapeutics plc - Advanced Valuation Insights
This section examines the relationship between Adaptimmune Therapeutics plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.66 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | -13.0% |
| Total Assets | €245.96 Million |
| Market Capitalization | $42.94 Million USD |
Valuation Analysis
Below Book Valuation: The market values Adaptimmune Therapeutics plc's assets below their book value (0.17x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Adaptimmune Therapeutics plc's assets decreased by 13.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Adaptimmune Therapeutics plc (2016–2024)
The table below shows the annual total assets of Adaptimmune Therapeutics plc from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €245.96 Million ≈ $287.56 Million |
-12.97% |
| 2023-12-31 | €282.62 Million ≈ $330.41 Million |
-14.08% |
| 2022-12-31 | €328.92 Million ≈ $384.54 Million |
-29.95% |
| 2021-12-31 | €469.55 Million ≈ $548.95 Million |
+4.08% |
| 2020-12-31 | €451.14 Million ≈ $527.43 Million |
+148.50% |
| 2019-12-31 | €181.54 Million ≈ $212.24 Million |
-34.40% |
| 2018-12-31 | €276.74 Million ≈ $323.53 Million |
-1.57% |
| 2017-12-31 | €281.15 Million ≈ $328.69 Million |
+19.88% |
| 2016-12-31 | €234.51 Million ≈ $274.17 Million |
-- |
About Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatmen… Read more